Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Replication timing alterations in leukemia reflect stable clinically-relevant changes in genome architecture

ABSTRACT: Replication timing alterations in leukemia reflect stable clinically-relevant changes in genome architecture

PROVIDER: PRJNA539934 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR8978510.fastq.gz	Fastqsanger.gz
	SRR8978520.fastq.gz	Fastqsanger.gz
	SRR8978530.fastq.gz	Fastqsanger.gz
	SRR8978540.fastq.gz	Fastqsanger.gz
	SRR8978550.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 48

Similar Datasets

Replication timing alterations in leukemia reflect stable clinically-relevant changes in genome architecture [Repli-Seq]

Project description:Replication timing alterations in leukemia reflect stable clinically-relevant changes in genome architecture [Repli-Seq]

| PRJNA539936 | ENA

Replication timing alterations in leukemia reflect stable clinically-relevant changes in genome architecture [Repli-Chip]

Project description:Replication timing alterations in leukemia reflect stable clinically-relevant changes in genome architecture [Repli-Chip]

| PRJNA539935 | ENA

Replication timing alterations in leukemia reflect stable clinically-relevant changes in genome architecture [Repli-Seq]

Project description:Human B-lineage precursor acute lymphoid leukemias (BCP-ALLs) comprise a group of genetically and clinically distinct disease entities with features of differentiation arrest at known stages of normal B-lineage differentiation. We previously showed BCP-ALL cells display unique and clonally heritable DNA-replication timing (RT) programs; i.e., programs describing the variable order of replication and sub-nuclear 3D architecture of megabase-scale chromosomal units of DNA in different cell types. To determine the extent to which BCP-ALL RT programs mirror or deviate from specific stages of normal human B-cell differentiation, we transplanted immunodeficient mice with quiescent normal human CD34+ cord blood cells and obtained RT signatures of the regenerating B-lineage populations. We then compared these with RT signatures for leukemic cells from a large cohort of BCP-ALL patients of varied genetic subtype and outcome. The results identify BCP-ALL subtype-specific features that resemble specific stages of B-cell differentiation and features that appear associated with relapse. These results suggest the genesis of BCP-ALL involves alterations in RT that reflect biologically significant and clinically relevant leukemia-specific epigenetic changes that have potential as a novel genre of prognostic biomarkers.

2019-12-27 | GSE130373 | GEO

Replication timing alterations in leukemia reflect stable clinically-relevant changes in genome architecture [Repli-Chip]

2019-12-27 | GSE130372 | GEO

Anti-inflammatory Chromatinscape Associated with Clinically Relevant Timing of Glucocorticoid Treatment

Project description:Anti-inflammatory Chromatinscape Associated with Clinically Relevant Timing of Glucocorticoid Treatment

| PRJNA362226 | ENA

Replication timing alterations in leukemia reflect stable clinically-relevant changes in genome architecture

Project description:This SuperSeries is composed of the SubSeries listed below.

2019-12-27 | GSE130374 | GEO

10 Intellectual Disability samples for clinically relevant CNV detection

Project description:10 patients with Intellectual Disability diagnosed with a clinically relevant copy number change, selected to assess the dection performance of alternative platforms.

2013-08-01 | GSE46060 | GEO

10 Intellectual Disability samples for clinically relevant CNV detection

Project description:10 patients with Intellectual Disability diagnosed with a clinically relevant copy number change, selected to assess the dection performance of alternative platforms. 10 Affymetrix arrays were performed according to the manufacturer's directions on DNA extracted from peripheral blood samples.

2013-08-01 | E-GEOD-46060 | biostudies-arrayexpress

Molecular characterization of choroid plexus tumors reveals novel clinically relevant subgroups

Project description:Molecular characterization of choroid plexus tumors reveals novel clinically relevant subgroups

| PRJNA259766 | ENA

Anti-inflammatory Chromatinscape Associated with Clinically Relevant Timing of Glucocorticoid Treatment [ChIP-seq]

Project description:Despite the widespread use of glucocorticoids (GCs) for treating inflammatory conditions, the underlying mechanisms of their anti-inflammatory effects are not understood. Moreover, the majority of molecular investigations have examined the effects of glucocorticoid receptor (GR) activation prior to inflammatory challenges. However, clinically relevant situations are emulated by a GC intervention initiated in the midst of rampant inflammatory responses. To characterize the effects of a late GC treatment, we performed systematic profiling of macrophage transcriptional and regulatory landscapes with Dexamethasone (Dex) treatment either before or after stimulation by lipopolysaccharide (LPS). GR activation by Dex following LPS stimulation had a similar anti-inflammatory profile in comparison to GR pre-activation, while ameliorating the disruption of metabolic genes. Unexpectedly, the chromatin occupancy pattern of GR is not predictive of the Dex-regulated expression changes and shows little evidence for the widely accepted ‘trans-repression by tethering’ model. Rather, we find that GR activation results in global blockade of NF-κB binding to chromatin. Integrative analyses of gene expression, transcription factor occupancy, and chromatin accessibility data highlight distinct mechanisms through which GR controls inflammatory macrophages: prevention of NF-κB chromatin occupancy and activation of negative regulators such as Nfkbia, Dusp1, Tnfaip3, and Tsc22d3. Our investigation with differentially timed GC treatments reveals molecular mechanisms underlying therapeutic actions of GR for modulating the ‘inflamed epigenome’.

2017-08-08 | GSE93736 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data